Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Acthib, Omnihib Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.
This Acthib, Omnihib market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
ActHIB and OmniHIB are vaccines designed to protect against invasive diseases caused by Haemophilus influenzae type b (Hib), including conditions such as meningitis and pneumonia. ActHIB is a conjugate vaccine, which combines the Hib capsular polysaccharide with a protein, while OmniHIB is a similar conjugate vaccine. Both vaccines are primarily given to infants and children to help build immunity. They play a vital role in preventing Hib-related illnesses, which can be severe or fatal.
The acthib, omnihib market consists of sales of Hib vaccines, boosters, and pediatric vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Market growth during the historical period can be attributed to the expansion of global immunization programs, increased pediatric vaccination rates, a surge in Hib disease outbreaks, higher adoption of combination vaccines, and growing public awareness of vaccine-preventable diseases. Market growth during the forecast period is driven by increasing awareness and efforts to control Hib infections, a rise in the incidence of Hib-related infections, expanding immunization rates, greater use of antibiotics and glucocorticoids, and the rising prevalence of chronic diseases. Key trends during the forecast period include advancements in pediatric vaccination, improvements in vaccine technology, innovation and new product developments, and progress in vaccine delivery systems.
The growing prevalence of Haemophilus influenzae type b (Hib) infections is expected to drive the growth of the ActHIB and OmniHIB market. Haemophilus influenzae type b infections are serious bacterial infections caused by the Haemophilus influenzae type b bacteria, which can lead to conditions such as meningitis, pneumonia, and epiglottitis, primarily affecting young children. The rise in Hib infections can be attributed to factors such as declining vaccination rates, the emergence of antibiotic resistance, and limited access to healthcare in certain regions.
ActHIB and OmniHIB vaccines are designed to protect against Hib infections by stimulating the immune system to recognize and combat the bacteria. For example, a report from the European Centre for Disease Prevention and Control (ECDC) in July 2024 noted a significant increase in confirmed cases of invasive Haemophilus influenzae disease, with 3,967 cases reported in 2022, a sharp rise from 1,694 cases in 2021. This increasing prevalence of Hib infections is driving the demand for ActHIB and OmniHIB vaccines.
The rise in healthcare expenditure is expected to support the growth of the ActHIB and OmniHIB market. Healthcare expenditure refers to the total spending on healthcare services, including personal care, preventive services, and public health activities aimed at improving health outcomes. This expenditure is increasing due to factors such as an aging population, rising chronic diseases, advanced medical technology, high drug costs, and inefficiencies in payment models, along with a growing demand for healthcare services.
As healthcare spending increases, it can enhance the accessibility and affordability of vaccines such as ActHIB and OmniHIB, thereby influencing vaccination rates and public health outcomes. For instance, in May 2024, the Office for National Statistics in the UK reported a 5.6% rise in total healthcare expenditure from 2022 to 2023, compared to a growth rate of just 0.9% the previous year. Additionally, long-term health and social care expenditure grew by 2.8% in real terms in 2022. As a result, rising healthcare expenditure is contributing to the growth of the ActHIB and OmniHIB market.
Advancements in biopharmaceutical solutions are another key factor driving growth in the ActHIB and OmniHIB market. A significant trend is the development of innovative combination vaccines that provide broader protection against multiple diseases while reducing the number of shots needed for immunization. A conjugate vaccine, which combines a bacterial polysaccharide with a protein to boost the immune response, is an example of such an innovation.
Key Topics Covered:
1. Executive Summary
2. Acthib, Omnihib Market Characteristics
3. Acthib, Omnihib Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route of Administration (ROA)
3.3. Mechanism of Action (MOA)
3.4. Safety and Efficacy
4. Acthib, Omnihib Market Trends and Strategies
5. Acthib, Omnihib Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
6. Global Acthib, Omnihib Growth Analysis and Strategic Analysis Framework
6.1. Global Acthib, Omnihib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis of End Use Industries
6.3. Global Acthib, Omnihib Market Growth Rate Analysis
6.4. Global Acthib, Omnihib Historic Market Size and Growth, 2019-2024, Value ($ Million)
6.5. Global Acthib, Omnihib Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)
6.6. Global Acthib, Omnihib Total Addressable Market (TAM)
7. Global Acthib, Omnihib Pricing Analysis & Forecasts
8. Acthib, Omnihib Market Segmentation
8.1. Global Acthib, Omnihib Market, Segmentation by Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
- Monovalent Hib Vaccines
- Combination Vaccines
8.2. Global Acthib, Omnihib Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
- Haemophilus Influenzae Type B (HIB) Infection
8.3. Global Acthib, Omnihib Market, Segmentation by Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
- Infants and Toddlers
- Adults
8.4. Global Acthib, Omnihib Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
- Hospitals and Clinics
- Retail Pharmacies
9. Global Acthib, Omnihib Epidemiology of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence and Prevalence of Clinical Indications
10. Acthib, Omnihib Market Regional and Country Analysis
10.1. Global Acthib, Omnihib Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Acthib, Omnihib Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
For more information about this report visit https://www.researchandmarkets.com/r/cwjp78
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
